Botanical Drug GM-XANTHO® Completes Phase I/IIa Trial for Atopic Dermatitis
Exhibitor: XANTHO BIOTECHNOLOGY CO., LTD.
Date: 2026-06-04
Booth No.: M434
Xanthon Bio is a botanical drug development company specializing in inflammatory skin diseases. Our R&D team has successfully extracted active ingredients from mangosteen to develop GM-XANTHO®, a topical cream that offers new hope to patients suffering from atopic dermatitis by effectively treating inflammation, itching, and redness. GM-XANTHO® has completed Phase I/IIa clinical trials in Taiwan, showing highly positive efficacy data and proving to be safe with no side effects for long-term use—a breakthrough alternative for those fearing steroid side effects. Having secured patents in the US, Europe, and Japan, we are now launching next-stage clinical trial plans in the US and Europe to drive global commercialization. At Bio Asia Taiwan, we are actively seeking partners for regional licensing or joint development to accelerate product launch and benefit patients worldwide.
More Exhibitor's Press Release
- MarkerX Unveils AI-Driven Next-Gen Mass Spec Proteomics Platform in Strategic Alliance with Nanomics MARKER X CO., LTD. / 2026-07-15
- Dasher Neuroscience Signs MOU with Norwegian Research Center to Join the Platform Trial HYDRA DASHER NEUROSCIENCE HOLDINGS INC. / 2026-07-15
- Dasher-KY Progresses Phase II AI Drug for MSA, Initiating International Licensing Steps DASHER NEUROSCIENCE HOLDINGS INC. / 2026-07-15
- TaiMed Launches "Rooting for Love" Charity Campaign in Support of Taiwan Lourdes Association TAIMED BIOLOGICS INC. / 2026-07-15
- Exhibition Preview | Youlin Pharma sincerely invites you to attend BIO Asia-Taiwan 2026 SHANGHAI UNIONCLIN CO,. LTD.(UNIONCLIN) / 2026-07-14
- MicroDoctor Cosmetics Showcases Advanced Dissolving Microneedle Technology at BIO Asia MICRODOCTOR BIOMEDICAL CORPORATION / 2026-07-14
- Wireless × Complete Recording × Traceability BrainChild DRS Powers Smarter Decisions BRAINCHILD ELECTRONIC CO., LTD. / 2026-07-14
- BrainChild PRV2.0 Precision Measurement Built for Accuracy, Reliability and Better Decisions BRAINCHILD ELECTRONIC CO., LTD. / 2026-07-14
- TaiMed unveil NextGen TMB-365 CD4-Targeted ADC Platform for HIV Functional Cure at 2026 BIO Asia TAIMED BIOLOGICS INC. / 2026-07-13
- Italian Trade Agency (ITA) in BIO ASIA 2026 -EXOLAB ITALIAN ECONOMIC, TRADE AND CULTURAL PROMOTION OFFICE IN TAIPEI TRADE SECTION / 2026-07-13
- Italian Trade Agency (ITA) in BIO ASIA 2026 - MENARINI ITALIAN ECONOMIC, TRADE AND CULTURAL PROMOTION OFFICE IN TAIPEI TRADE SECTION / 2026-07-13
- Italian Trade Agency (ITA) in BIO ASIA 2026 - DEAKOS ITALIAN ECONOMIC, TRADE AND CULTURAL PROMOTION OFFICE IN TAIPEI TRADE SECTION / 2026-07-13
- Taiwan Bio partners with Terumo Blood and Cell Technologies to advance automated Treg manufacturing TERUMO BCT ASIA PTE. LTD. / 2026-07-13
- Terumo BCT and Steminent Collaborate to Advance MSC Late-Stage Clinical Manufacturing TERUMO BCT ASIA PTE. LTD. / 2026-07-13
- Terumo Blood and Cell Technologies Introduces APAC CGT Ecosystem Blueprint TERUMO BCT ASIA PTE. LTD. / 2026-07-13
- [Exhibition News] UVAT to Showcase Breakthrough Technologies at BIO Asia-Taiwan 2026! UVAT TECHNOLOGY CO., LTD. / 2026-07-09
- Painless Decoding, Seamless Tracking: Letting Singular Wings Medical's AI Navigate Your Metabolism. SINGULAR WINGS MEDICAL / 2026-07-08
- TaiMed showcase CD4-Targeted platform breakthroughs and High-Quality CDMO Solutions at 2026 BIO Asia TAIMED BIOLOGICS INC. / 2026-07-08
- Lonza Advances Integrated DNA to IND Programs Through Acceleration, De-Risking, and Innovation LONZA / 2026-07-08
- Lonza Acquires Rights to Nona Biosciences’ TfR1 Blood-Brain Barrier Technology and Expands Strategic LONZA / 2026-07-08
